• Jonathan S Zager, Steven N Hochwald, Suroosh S Marzban, Rony Francois, Kimberly M Law, Ashley H Davis, Jane L Messina, Vladimir Vincek, Christina Mitchell, Ann Church, Edward M Copeland, Vernon K Sondak, and Stephen R Grobmyer.
• Department of Cutaneous Oncology, Moffitt Cancer Center, and the University of South Florida College of Medicine, Tampa, FL 33612, USA. jonathan.zager@moffitt.org
• J. Am. Coll. Surg. 2011 Apr 1; 212 (4): 454-60; discussion 460-2.

BackgroundShave biopsy of cutaneous lesions is simple, efficient, and commonly used clinically. However, this technique has been criticized for its potential to hamper accurate diagnosis and microstaging of melanoma, thereby complicating treatment decision-making.Study DesignWe retrospectively analyzed a consecutive series of patients referred to the University of Florida Shands Cancer Center or to the Moffitt Cancer Center for treatment of primary cutaneous melanoma, initially diagnosed on shave biopsy to have Breslow depth < 2 mm, to determine the accuracy of shave biopsy in T-staging and the potential impact on definitive surgical treatment and outcomes.ResultsSix hundred patients undergoing shave biopsy were diagnosed with melanoma from extremity (42%), trunk (37%), and head or neck (21%). Mean (± SEM) Breslow thickness was 0.73 ± 0.02 mm; 6.2% of lesions were ulcerated. At the time of wide excision, residual melanoma was found in 133 (22%), resulting in T-stage upstaging for 18 patients (3%). Recommendations for additional wide excision or sentinel lymph node biopsy changed in 12 of 600 (2%) and 8 of 600 patients (1.3%), respectively. Locoregional recurrence occurred in 10 (1.7%) patients and distant recurrence in 4 (0.7%) patients.ConclusionsThese data challenge the surgical dogma that full-thickness excisional biopsy of suspicious cutaneous lesions is the only method that can lead to accurate diagnosis. Data obtained on shave biopsy of melanoma are reliable and accurate in the overwhelming majority of cases (97%). The use of shave biopsy does not complicate or compromise management of the overwhelming majority of patients with malignant melanoma.Copyright © 2011 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

24 keywords...

hide…